RESUMEN
BACKGROUND: Systemic mastocytosis (SM) is a clonal disorder of mast cells (MCs) frequently associated with vertebral osteoporosis (OP) and subsequent vertebral fractures (VFs). The natural history of this OP remains unclear. Importantly, we do not know whether OP represents an early event triggered alongside MC abnormalities, and whether MC clonality is sufficient to trigger osteoporosis. OBJECTIVE: To describe OP in patients with medullar clonality in cutaneous mastocytosis (CM) and monoclonal mast cell activation syndrome (MMAS) and to compare their osteoporosis characteristics with those of nonadvanced SM patients (bone marrow mastocytosis and indolent systemic mastocytosis). METHODS: We retrospectively analyzed clinical, biological, and densitometric data of 27 CM, 13 MMAS, and 135 SM patients from the Mastocytosis Expert Center (CEREMAST) in Toulouse, France. RESULTS: The OP (respectively 3.7, 30.8, and 34.1%) and VFs (0.0%, 15.4%, and 20%) were less frequent in CM than in MMAS and SM, despite the presence of clonal MCs in the bone marrow. Most patients with OP and VFs in the non-SM groups had the usual risk factors for OP. Interestingly, the only non-SM patient with a typical SM-like OP had high bone marrow tryptase, developed bone marrow KIT mutation during follow-up, and had a family history of SM. Our data show that OP is not a common clinical finding in CM but is frequent in MMAS. When OP and VFs occur in CM and MMAS patients, they differ from the usual phenotype of SM bone fragility. CONCLUSIONS: Our findings suggest that, in most CM patients, the meaning and management of OP differs from that of OP in MMAS and nonadvanced SM. Prospective longitudinal studies and the validation of predictors are needed to identify CM and MMAS patients developing SM-related OP.
Asunto(s)
Mastocitosis Cutánea , Mastocitosis Sistémica , Osteoporosis , Humanos , Osteoporosis/epidemiología , Femenino , Masculino , Persona de Mediana Edad , Adulto , Prevalencia , Estudios Retrospectivos , Anciano , Mastocitosis Cutánea/epidemiología , Mastocitosis Sistémica/epidemiología , Mastocitos/inmunología , Francia/epidemiología , Médula Ósea/patología , Proteínas Proto-Oncogénicas c-kit/genética , Fracturas de la Columna Vertebral/epidemiologíaRESUMEN
There has been limited research exploring how the demographic characteristics of children with pediatric cutaneous mastocytosis (PCM) may influence both the cutaneous and systemic symptoms. In this observational retrospective study of 51 children with PCM, we found a significantly higher rate of gastrointestinal (GI) symptoms in children of Hispanic ethnicity (4/21,19%) compared to non-Hispanics (0/30, 0%, p = 0.024). While this finding may reflect the high proportion of Hispanics in our population, a racial predisposition toward distinct systemic symptoms may be possible. We also found a significantly lower proportion of Hispanic children being diagnosed with PCM under the age of 3 years (47.6%) when compared with non-Hispanic children (76.7%, p = 0.03), suggesting that more data are needed to further assess the role of ethnicity and healthcare disparities in PCM diagnosis. Larger prospective studies are necessary to better evaluate the association between ethnicity, early diagnosis, and systemic symptoms in PCM and to describe its impact on long-term outcomes.
Asunto(s)
Etnicidad , Mastocitosis Cutánea , Humanos , Niño , Preescolar , Estudios Retrospectivos , Estudios Prospectivos , Hispánicos o Latinos , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/epidemiologíaRESUMEN
BACKGROUND: Mastocytosis is a heterogeneous group of rare disorders characterized by the accumulation of clonal mast cells in organs such as the skin and bone marrow. The diagnosis of cutaneous mastocytosis (CM) is based on clinical findings, positive Darier's sign, and histopathology, if necessary. METHODS: Medical records of 86 children with CM diagnosed during a 35-year long period were reviewed. Most patients (93%) developed CM during the first year of life (median age 3 months). Clinical features at presentation and during the follow-up period were analyzed. Baseline serum tryptase level was measured in 28 patients. RESULTS: A total of 85% of patients had maculopapular cutaneous mastocytosis/urticaria pigmentosa (MPCM/UP), 9% had mastocytoma, and 6% had diffuse cutaneous mastocytosis (DCM). Boy to girl ratio was 1.1:1. Fifty-four of 86 patients (63%) were followed from 2 to 37 years (median 13 years). Complete resolution was registered in 14% of mastocytoma cases, 14% of MCPM/UP, and in 25% of DCM patients. After the age of 18, skin lesion persisted in 14% mastocytoma, 7% MCPM/UP, and 25% children with DCM. Atopic dermatitis was diagnosed in 9.6% of patients with MPCM/UP. Three of 28 patients had elevated serum tryptase. Prognosis in all patients was good, and there were no signs of progression to systemic mastocytosis (SM). CONCLUSION: To the best of our knowledge, our results represent the longest single-center follow-up study of childhood-onset CM. We found no complications of massive mast cell degranulation or progression to SM.
Asunto(s)
Mastocitoma , Mastocitosis Cutánea , Mastocitosis Sistémica , Mastocitosis , Urticaria Pigmentosa , Masculino , Femenino , Humanos , Niño , Lactante , Estudios de Seguimiento , Triptasas , Mastocitosis/diagnóstico , Mastocitosis/epidemiología , Mastocitosis/patología , Urticaria Pigmentosa/diagnóstico , Urticaria Pigmentosa/patología , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/patología , Mastocitos/patología , Mastocitosis Sistémica/diagnóstico , Mastocitoma/patologíaAsunto(s)
Mastocitosis Cutánea , Mastocitosis Sistémica , Mutación Missense , Proteínas Proto-Oncogénicas c-kit/genética , Adolescente , Adulto , Anciano , Sustitución de Aminoácidos , Familia , Femenino , Humanos , Masculino , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/genética , Mastocitosis Sistémica/genética , Mastocitosis Sistémica/metabolismo , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
Mastocytosis is a rare neoplasm characterized by the expansion and accumulation of mast cells in various organ systems. Systemic mastocytosis (SM) may or may not present with cutaneous lesions. To examine the frequency and clinical impact of cutaneous involvement, data on 1,510 patients with mastocytosis collected in the registry of the European Competence Network on Mastocytosis were analyzed. Cutaneous involvement was found in 1,195 of 1,510 patients (79.1%). Of these, 286 had cutaneous mastocytosis, and 721 had SM with skin involvement. Adult patients with skin involvement who did not have a bone marrow examination (n = 188) were defined as having mastocytosis in the skin. In 315 patients, SM without skin involvement was found. The percentage of cases with cutaneous involvement was higher in indolent SM (100%) and smoldering SM (87.9%) compared to aggressive SM (46.8%) or mast cell leukemia (38.5%). After a median follow-up of 5.6 years, no patient with cutaneous mastocytosis had died, but 2.6% of the patients with mastocytosis in the skin, 5.7% of the patients with SM with skin involvement, and 28.95% of the patients with SM without skin involvement had died. Overall survival was longer in patients with skin involvement (cutaneous mastocytosis and/or mastocytosis in the skin and/or SM with skin involvement) than in patients with SM without skin involvement (P < 0.0001). These data argue for a thorough examination of both the skin and bone marrow in adult patients with mastocytosis.
Asunto(s)
Mastocitos/patología , Mastocitosis Cutánea/diagnóstico , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/mortalidad , Piel/patología , Adolescente , Adulto , Anciano , Biopsia , Médula Ósea/patología , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Humanos , Lactante , Masculino , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/patología , Mastocitosis Sistémica/patología , Persona de Mediana Edad , Pronóstico , Sistema de Registros/estadística & datos numéricos , Análisis de Supervivencia , Factores de Tiempo , Adulto JovenRESUMEN
Immunization compliance in the United States is declining, in part due to misinformation and fear surrounding adverse vaccination reactions. Recently, there have been data published in the allergy and immunology literature to show that there may be a relationship between routine vaccinations and induction of symptoms in cutaneous mastocytosis patients; however, this has not yet been explored in the dermatology literature. We sought to uncover the prevalence of vaccine reactions due to mast cell activation within our cohort of maculopapular cutaneous mastocytosis (MPCM) patients in order to contribute to ensuring administration safety, managing familial expectations, and encouraging continued adherence. Our results indicate that while incidence of reaction rates may be higher than the national average, they are mild and families should be counseled to follow recommended immunization schedule guidelines.
Asunto(s)
Hipersensibilidad , Mastocitosis Cutánea , Urticaria Pigmentosa , Niño , Humanos , Inmunización , Mastocitosis Cutánea/epidemiología , VacunaciónRESUMEN
BACKGROUND: Mastocytosis in adults often presents with skin lesions. A bone marrow biopsy is necessary to confirm or exclude the presence of systemic mastocytosis (SM) in these cases. When a bone marrow biopsy is not performed, the provisional diagnosis is mastocytosis in the skin (MIS). No generally accepted scoring system has been established to estimate the risk of SM in these patients. OBJECTIVE: To develop a risk score to predict SM in adults with MIS. METHODS: We examined 1145 patients with MIS from the European Competence Network on Mastocytosis Registry who underwent a bone marrow biopsy. A total of 944 patients had SM and 201 patients had cutaneous mastocytosis; 63.7% were female, and 36.3% were male. Median age was 44 ± 13.3 years. The median serum tryptase level amounted to 29.3 ± 81.9 ng/mL. We established a multivariate regression model using the whole population of patients as a training and validation set (bootstrapping). A risk score was developed and validated with receiver-operating curves. RESULTS: In the multivariate model, the tryptase level (P < .001), constitutional/cardiovascular symptoms (P = .014), and bone symptoms/osteoporosis (P < .001) were independent predictors of SM (P < .001; sensitivity, 90.7%; specificity, 69.1%). A 6-point risk score was established (risk, 10.7%-98.0%) and validated. CONCLUSIONS: Using a large data set of the European Competence Network on Mastocytosis Registry, we created a risk score to predict the presence of SM in patients with MIS. Although the score will need further validation in independent cohorts, our score seems to discriminate safely between patients with SM and with pure cutaneous mastocytosis.
Asunto(s)
Mastocitosis Cutánea , Mastocitosis Sistémica , Mastocitosis , Adulto , Médula Ósea , Femenino , Humanos , Masculino , Mastocitos , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/epidemiología , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/epidemiología , Persona de Mediana Edad , TriptasasRESUMEN
BACKGROUND/OBJECTIVES: Though maculopapular cutaneous mastocytosis is the most common form of pediatric mastocytosis, it remains unclear which patients will experience severe symptoms. We sought to better define the presentation and the cutaneous and systemic signs and symptoms in patients with maculopapular cutaneous mastocytosis. METHODS: We analyzed retrospective data on 227 patients diagnosed with maculopapular cutaneous mastocytosis prior to age 15 years from five US clinical sites. We collected data on signs, symptoms, age of onset, and laboratory testing. RESULTS: Median age of onset of maculopapular cutaneous mastocytosis was 3 months, with 94% of patients presenting prior to age 2 (range 0-15 years). Patients presenting before age 2 had significantly lower serum tryptase level (P = .019). Greater number of skin lesions (P = .006), number of reported skin signs and symptoms (P < .001), and higher tryptase levels (P < .001) were associated with more systemic symptoms. CONCLUSION: Children with maculopapular cutaneous mastocytosis, who have greater skin involvement, higher serum tryptase level, and more skin signs and symptoms, are more likely to have systemic symptoms.
Asunto(s)
Mastocitosis Cutánea , Mastocitosis , Urticaria Pigmentosa , Adolescente , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/epidemiología , Estudios Retrospectivos , Piel , Triptasas , Urticaria Pigmentosa/diagnóstico , Urticaria Pigmentosa/epidemiologíaRESUMEN
The coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase, and patients at risk can only be protected to a degree, because the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. Because no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Although the overall risk to acquire the severe acute respiratory syndrome coronavirus 2 may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain comorbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system, and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. In contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/epidemiología , Manejo de la Enfermedad , Mastocitosis Cutánea/tratamiento farmacológico , Mastocitosis Sistémica/tratamiento farmacológico , Pandemias , Neumonía Viral/epidemiología , Betacoronavirus/inmunología , COVID-19 , Comorbilidad , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/patología , Difosfonatos/uso terapéutico , Testimonio de Experto , Glucocorticoides/efectos adversos , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Inmunosupresores/efectos adversos , Mastocitos/efectos de los fármacos , Mastocitos/inmunología , Mastocitos/patología , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/patología , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/epidemiología , Mastocitosis Sistémica/patología , Agonistas Mieloablativos/efectos adversos , Neumonía Viral/diagnóstico , Neumonía Viral/patología , Medicina de Precisión/métodos , Factores de Riesgo , SARS-CoV-2 , Vitamina D/uso terapéuticoRESUMEN
BACKGROUND: Mastocytosis is characterized by the accumulation/proliferation of abnormal mast cells. The frequency of isolated cutaneous involvement in adults with mastocytosis has not been fully determined. The main objective of our study was to assess the frequency of isolated cutaneous mastocytosis (CM) in adults with mastocytosis skin lesions. The second objective was to compare the clinical, histological, biological and imaging features in patients with isolated CM and patients with systemic mastocytosis (SM). METHODS: We included all patients with histology-proven mastocytosis skin lesions between January 2009 and December 2017. The mastocytosis diagnosis was made according to the international diagnostic criteria. All data were collected from a dedicated specific case report. RESULTS: Among 160 patients with mastocytosis skin lesions, 25 patients had isolated CM (15.6%), 105 had SM and 30 (18.7%) patients had undetermined mastocytosis. Skin KIT mutation (OR: 51.9, 95% CI: 3.9-678, P = 0.001) and high bone marrow tryptase (OR: 97.4, 95% CI: 10.3-915, P = 0.001) were strong predictors of SM. The prevalence of osteoporosis was higher in the SM population than in the isolated CM population. Moreover, a decrease in bone mineral density over a short period of follow-up (1-2 years) was associated with SM. There were no differences between the two groups regarding the frequency of mast cell activation symptoms, the presentation of skin lesions, the number of mast cells in the dermis and the level of serum tryptase. We propose considering the KIT mutation status and bone marrow tryptase levels to aid the diagnosis of isolated CM in adult mastocytosis patients. CONCLUSION: Only a small minority of adults with mastocytosis skin lesions has isolated cutaneous involvement. In 18.7% of mastocytosis cases, even complete workup does not allow for a precise classification of patients.
Asunto(s)
Mastocitosis Cutánea/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/análisis , Biopsia , Densidad Ósea , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/genética , Persona de Mediana Edad , Mutación , Prevalencia , Proteínas Proto-Oncogénicas c-kit/genética , Triptasas/análisisRESUMEN
Little is known about osteoporosis in mast cell disorders (MCDs) not related to systemic mastocytosis. We described osteoporosis and fractures in MCDs and showed that systemic mastocytosis was the only studied MCDs associated with osteoporotic vertebral fractures. INTRODUCTION: To describe osteoporosis (OP) and fragility fractures in mast cell disorders (MCDs). METHODS: We retrospectively analyzed data concerning all successive patients with systemic mastocytosis (SM), cutaneous mastocytosis (CM), and mast cell activation syndromes (MCAS) diagnosed in our mastocytosis expert center between 2004 and 2015. We collected data concerning demographic profiles, clinical signs of MCD, osteoporosis, fractures, densitometry, and biological assessment of MCD. We compared CM and MCAS patients with SM patients with regard to the characteristics of OP and fragility fractures. RESULTS: We assessed 89 SM patients, 20 CM patients, and 20 MCAS patients. Osteoporosis was less frequent in CM (15.0%) and MCAS (10.0%) than in SM (44.9%). Similarly, fractures were less frequent in non-SM MCDs, respectively 5.0%, 5.0%, and 28.1%. SM patients displayed high prevalence of vertebral fractures (22.5%), mostly multiple. Conversely, in non-SM patients, vertebral fractures appeared to be uncommon (5%) and more frequently associated with risk factors for osteoporosis. CONCLUSIONS: SM is associated with multiple vertebral osteoporotic fractures, whereas CM and MCAS do not appear to be associated with this phenotype.
Asunto(s)
Mastocitosis/complicaciones , Fracturas Osteoporóticas/etiología , Fracturas de la Columna Vertebral/etiología , Adulto , Densidad Ósea/fisiología , Femenino , Francia/epidemiología , Articulación de la Cadera/fisiopatología , Humanos , Vértebras Lumbares/fisiopatología , Masculino , Mastocitosis/epidemiología , Mastocitosis/fisiopatología , Mastocitosis Cutánea/complicaciones , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/fisiopatología , Mastocitosis Sistémica/complicaciones , Mastocitosis Sistémica/epidemiología , Mastocitosis Sistémica/fisiopatología , Persona de Mediana Edad , Osteoporosis/epidemiología , Osteoporosis/etiología , Osteoporosis/fisiopatología , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/fisiopatología , Prevalencia , Estudios Retrospectivos , Fracturas de la Columna Vertebral/epidemiología , Fracturas de la Columna Vertebral/fisiopatologíaRESUMEN
BACKGROUND: Mast cell diseases such as mastocytosis and mast cell activation syndrome involve abnormal proliferation and/or activation of these cells, leading to many clinically relevant symptoms. OBJECTIVE: To determine the characteristics and experiences of people known or suspected to have a mast cell disorder, The Mastocytosis Society, a US-based patient advocacy, research, and education organization, conducted a survey of patients. METHODS: This Web-based survey was publicized through specialty clinics and the society's newsletter, Web site, and online blogs. Both online and paper copies of the questionnaire were provided together with required statements of consent. RESULTS: The first set of results from this survey of 420 respondents has been previously published; the second set is presented in this article. These results include source(s) of diagnosis, clinical and laboratory tests reported, comorbidities, dietary practices, possible familial occurrence of mast cell disorders, and perceptions concerning mast cell disorder-related medical care needs in the United States. CONCLUSIONS: These patient survey results are provided to assist medical professionals in learning patients' perceptions of their experiences and to give patients with mast cell disorders and caregivers the opportunity to compare experiences with those of other affected individuals.
Asunto(s)
Dieta , Familia , Mastocitosis Cutánea/diagnóstico , Mastocitosis Sistémica/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Alergólogos , Anafilaxia/diagnóstico , Anafilaxia/terapia , Densidad Ósea , Conservadores de la Densidad Ósea/uso terapéutico , Enfermedades Óseas Metabólicas/tratamiento farmacológico , Enfermedades Óseas Metabólicas/epidemiología , Calcio/uso terapéutico , Niño , Preescolar , Técnicas de Laboratorio Clínico , Dermatólogos , Dietoterapia , Femenino , Pruebas Genéticas , Conductas Relacionadas con la Salud , Humanos , Lactante , Masculino , Mastocitosis/diagnóstico , Mastocitosis/epidemiología , Mastocitosis/terapia , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/terapia , Mastocitosis Sistémica/epidemiología , Mastocitosis Sistémica/terapia , Persona de Mediana Edad , Evaluación de Necesidades , Oncólogos , Osteoporosis/tratamiento farmacológico , Osteoporosis/epidemiología , Médicos de Atención Primaria , Encuestas y Cuestionarios , Estados Unidos , Vitamina D/uso terapéutico , Adulto JovenRESUMEN
AIM: We collected 'real-life' data on the management of patients with mastocytosis in the Italian Mastocytosis Registry. METHODS: Six hundred patients diagnosed with mastocytosis between 1974 and 2014 were included from 19 centers. RESULTS: Among adults (n = 401); 156 (38.9%) patients were diagnosed with systemic mastocytosis. In 212 adults, no bone marrow studies were performed resulting in a provisional diagnosis of mastocytosis of the skin. This diagnosis was most frequently established in nonhematologic centers. In total, 182/184 pediatric patients had cutaneous mastocytosis. We confirmed that in the most patients with systemic mastocytosis, serum tryptase levels were >20 ng/ml and KIT D816V was detectable. CONCLUSION: The Italian Mastocytosis Registry revealed some center-specific approaches for diagnosis and therapy. Epidemiological evidence on this condition is provided.
Asunto(s)
Mastocitosis Cutánea/epidemiología , Mastocitosis Sistémica/epidemiología , Sistema de Registros/estadística & datos numéricos , Adolescente , Adulto , Médula Ósea/patología , Niño , Femenino , Humanos , Italia/epidemiología , Masculino , Mastocitosis Cutánea/diagnóstico , Mastocitosis Cutánea/genética , Mastocitosis Cutánea/patología , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/genética , Mastocitosis Sistémica/patología , Mutación , Prevalencia , Proteínas Proto-Oncogénicas c-kit/genética , Estudios Retrospectivos , Piel/patología , Triptasas/sangre , Adulto JovenRESUMEN
OBJECTIVES: To estimate prevalence of exposure to environmental tobacco smoke and other environmental toxins in dogs with primary lung tumours and to analyse association between exposure and lung tumour development. MATERIALS AND METHODS: In this case-control study, an owner survey was developed to collect data on patient characteristics, general health care and environmental exposures. Dogs diagnosed with primary lung carcinomas formed the Case group. Dogs diagnosed with mast cell tumours served as Control Group 1 and dogs diagnosed with neurologic disease served as Control Group 2. Associations between diagnosis of primary lung tumour and patient and environmental exposure variables were analysed using bivariate and multivariate statistical methods. RESULTS: A total of 1178 owner surveys were mailed and 470 surveys were returned and included in statistical analysis, including 135 Cases, 169 dogs in Control Group 1 and 166 dogs in Control Group 2. An association between exposure to second-hand smoke and prevalence of primary lung cancer was not identified in this study. CLINICAL SIGNIFICANCE: Second-hand smoke is associated with primary lung cancer in people but a definitive association has not been found in dogs. The results of this study suggest that tobacco smoke exposure may not be associated with primary lung cancer development in dogs but study limitations may have precluded detection of an association.
Asunto(s)
Enfermedades de los Perros/epidemiología , Neoplasias Pulmonares/veterinaria , Contaminación por Humo de Tabaco/efectos adversos , Contaminación del Aire Interior/efectos adversos , Animales , Estudios de Casos y Controles , Perros , Exposición a Riesgos Ambientales/efectos adversos , Humanos , Neoplasias Pulmonares/epidemiología , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/veterinaria , Enfermedades del Sistema Nervioso/epidemiología , Enfermedades del Sistema Nervioso/veterinaria , Factores de Riesgo , Encuestas y CuestionariosRESUMEN
Grade II mast cell tumours (MCT) are tumours with variable biologic behaviour. Multiple factors have been associated with outcome, including proliferation markers. The purpose of this study was to determine if extent of surgical excision affects recurrence rate in dogs with grade II MCT with low proliferation activity, determined by Ki67 and argyrophilic nucleolar organising regions (AgNOR). Eighty-six dogs with cutaneous MCT were evaluated. All dogs had surgical excision of their MCT with a low Ki67 index and combined AgNORxKi67 (Ag67) values. Twenty-three (27%) dogs developed local or distant recurrence during the median follow-up time. Of these dogs, six (7%) had local recurrence, one had complete and five had incomplete histologic margins. This difference in recurrence rates between dogs with complete and incomplete histologic margins was not significant. On the basis of this study, ancillary therapy may not be necessary for patients with incompletely excised grade II MCT with low proliferation activity.
Asunto(s)
Antígenos Nucleares/metabolismo , Enfermedades de los Perros/metabolismo , Antígeno Ki-67/metabolismo , Mastocitosis Cutánea/veterinaria , Recurrencia Local de Neoplasia/veterinaria , Animales , Biomarcadores de Tumor/metabolismo , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/cirugía , Perros , Femenino , Estimación de Kaplan-Meier , Masculino , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/metabolismo , Mastocitosis Cutánea/cirugía , Recurrencia Local de Neoplasia/epidemiología , Recurrencia Local de Neoplasia/metabolismo , Recurrencia Local de Neoplasia/cirugía , Estadificación de Neoplasias/veterinaria , Países Bajos/epidemiología , Estudios Retrospectivos , Resultado del TratamientoAsunto(s)
Discapacidades para el Aprendizaje/epidemiología , Mastocitosis Cutánea/epidemiología , Adolescente , Niño , Preescolar , Estudios de Cohortes , Humanos , Discapacidades para el Aprendizaje/diagnóstico , Proyectos Piloto , Prevalencia , Sensibilidad y Especificidad , Encuestas y CuestionariosRESUMEN
Mastocytosis comprises a heterogeneous group of disorders characterized by clonal, neoplastic proliferation of mast cells accumulating in one or multiple organs. In the majority of cases skin involvement is the first clinical manifestation of the disease. Clinical work-up consists of a combination of morphological, immunohistochemical, flow cytometric immunophenotyping and molecular examination. Cutaneous mastocytosis predominates in children, whereas systemic mastocytosis is the most common form of the disease in adults. Therefore, different diagnostic algorithms have to be applied in adult patients and children with suspected mastocytosis. This comprehensive review presents currently defined variants of the disease and recommendations to facilitate diagnostic work-up in children and adults with suspected mastocytosis in daily clinical practice.
Asunto(s)
Mastocitosis Cutánea/diagnóstico , Mastocitosis Sistémica/diagnóstico , Adulto , Edad de Inicio , Niño , Diagnóstico Diferencial , Humanos , Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/terapia , Mastocitosis Sistémica/epidemiología , Mastocitosis Sistémica/terapia , Valor Predictivo de las Pruebas , PronósticoRESUMEN
BACKGROUND: Cutaneous mastocytosis (CM) is a typical presentation of mastocytosis in children. However, systemic mastocytosis may also occur in children. OBJECTIVE: We tried to characterize the clinical features of childhood-onset mastocytosis and estimate the value of the SCORMA (SCORing Mastocytosis) Index and serum tryptase levels as disease severity parameters. METHODS: In a survey of 101 children mastocytosis was diagnosed and classified according to World Health Organization criteria. In all the cases serum tryptase levels and the SCORMA Index were done to assess the extent and intensity of the disease. RESULTS: Cutaneous mastocytosis was diagnosed in 100 children; 84% of them presented maculopapular CM, 10% mastocytoma and 6% diffuse cutaneous mastocytosis. Moreover, systemic mastocytosis with bone marrow infiltration and associated with maculopapular CM was found in one case. There was a positive correlation of serum tryptase level to the SCORMA Index. Both the mean tryptase level and the mean SCORMA Index were elevated in diffuse cutaneous mastocytosis children when compared with other forms CM. A significantly higher mean tryptase level was found in children with flushing, hypotension, diarrhoea, extensive bullous lesions and osteoporosis or osteopenia. CONCLUSION: Mastocytosis in children usually has a benign course. Nevertheless, severe mediator-related symptoms and systemic involvement may appear. Therefore, a multidisciplinary approach involving careful monitoring of the serum tryptase level, SCORMA Index and the organ function is recommended. Both tryptase levels and the SCORMA Index are of a great value as disease severity parameters and they should be assessed simultaneously in all mastocytosis patients.
Asunto(s)
Mastocitosis Cutánea/epidemiología , Mastocitosis Cutánea/patología , Mastocitosis Sistémica/patología , Triptasas/metabolismo , Adolescente , Distribución por Edad , Biopsia con Aguja , Niño , Preescolar , Estudios Transversales , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Incidencia , Lactante , Masculino , Mastocitosis Cutánea/diagnóstico , Mastocitosis Sistémica/diagnóstico , Mastocitosis Sistémica/epidemiología , Polonia/epidemiología , Pronóstico , Enfermedades Raras , Medición de Riesgo , Índice de Severidad de la Enfermedad , Distribución por Sexo , Triptasas/análisisRESUMEN
Mastocytosis are characterized by an accumulation of abnormal mast cells in various tissues. Their incidence is estimated at 1/150,000 patients. Pure cutaneous mastocytosis which are mainly observed during childhood may resolve spontaneously during adolescence, whereas systemic mastocytosis involving one or more organs or tissues are more observed in adults. The initial event leading to mastocytosis is believed to be related to activating mutations in c-kit receptor, thus resulting in increased proliferation of mast cells precursors, migration in various tissues and degranulation leading to clinical signs. This nosologic entity does not belong to allergic diseases. Their perioperative management involves a multidisciplinary approach. The degranulation of mast cells with subsequent clinical symptoms can be triggered by psychological, chemical, traumatic, physical (rubbing, extreme temperatures...) agents. Avoiding these triggers should be realized whenever possible according to each patient. The premedication has not proven its efficiency. Tryptase measurement is part of the preoperative biological assessment. The clinical signs severity is related to the cardiovascular homeostasis disturbances (arterial hypotension, cardiovascular collapse, cardiac arrest). The cardiovascular symptoms do not correlate to the cutaneous versus systemic description of the disease. The drug of choice for the treatment of the severe cardiovascular signs is epinephrine associated to vascular loading. The aim of this literature review is to suggest the different modalities of perioperative care of patients with mastocytosis.